Erste Group Bank Has Positive Outlook of BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $6.29 per share for the year, up from their previous forecast of $6.28. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.12 EPS.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

BMY has been the topic of a number of other reports. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Barclays initiated coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Scotiabank reissued a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Citigroup boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Trading Up 2.7%

Shares of NYSE:BMY opened at $58.94 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The business has a 50 day moving average of $58.69 and a two-hundred day moving average of $52.06. The company has a market capitalization of $120.02 billion, a PE ratio of 17.08, a PEG ratio of 0.16 and a beta of 0.26.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds have recently bought and sold shares of BMY. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank lifted its position in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares in the last quarter. American Century Companies Inc. boosted its stake in Bristol Myers Squibb by 4.3% during the second quarter. American Century Companies Inc. now owns 2,354,441 shares of the biopharmaceutical company’s stock worth $108,987,000 after buying an additional 97,089 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at $1,403,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.